CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel therapeutic vaccine platform using Plasmacytoid Dendritic Cells to enhance the effectiveness of existing cancer immunotherapies, particularly for lung cancer patients. The goal is to improve response rates to treatment while minimizing toxicity and reducing the complexity of c…
Since 2014, the revolution of immuno-oncology gives unprecedented hope for cure to cancer patients thanks to immunotherapies such as anti-PD(L)-1.
However around 80% patients still don’t respond to anti-PD(L)-1.
Several barriers are still to be overcome to sustain the path of a novel paradigm responding both unmet therapeutic needs and health economy sustainability; cancer being estimated as a leading cause of deaths in Europe (350’000 deaths in 2012– Globocan) corresponding to an economical bur…
PDC LINE PHARMA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
